Streetbeat News

Price Targets

CFLT

Mizuho analyst Gregg Moskowitz maintains a Buy rating on Confluent (NASDAQ:CFLT) and raises the price target from $34 to $38.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 11:56 pm

AMAT

Mizuho analyst Vijay Rakesh maintains a Buy rating on Applied Materials (AMAT) and increases the price target from $185 to $225, indicating a positive outlook on the stock.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 11:55 pm

ITCI

Mizuho analyst Graig Suvannavejh maintains a Buy rating on Intra-Cellular Therapies (NASDAQ:ITCI) and raises the price target from $76 to $82.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 11:53 pm

IMCR

Mizuho analyst Graig Suvannavejh has maintained a Buy rating on Immunocore Holdings (IMCR) and increased the price target from $72 to $86. This adjustment reflects a positive outlook on the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 11:52 pm

HRMY

Mizuho analyst Graig Suvannavejh maintains a Buy rating on Harmony Biosciences (NASDAQ:HRMY) and raises the price target from $33 to $42.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 11:50 pm

EYPT

Mizuho analyst Graig Suvannavejh maintains a Buy rating on EyePoint Pharmaceuticals (NASDAQ:EYPT) and raises the price target from $30 to $39.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 11:48 pm

AXSM

Mizuho analyst Graig Suvannavejh maintains a Buy rating on Axsome Therapeutics (AXSM) and raises the price target from $90 to $112.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 11:48 pm

CERE

Mizuho analyst Graig Suvannavejh maintains a Neutral rating on Cerevel Therapeutics Hldg (NASDAQ:CERE) and raises the price target from $25 to $45.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 11:48 pm

APLS

Mizuho analyst Graig Suvannavejh has maintained a Neutral rating on Apellis Pharmaceuticals (NASDAQ:APLS) and increased the price target from $49 to $60.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 11:48 pm

SUM

Summit Materials' stock price increased following RBC Capital's decision to maintain a Sector Perform rating while raising its price target from $38 to $39.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 8:54 pm